吡非尼酮(Pirfenidone) - 在研适应症：特发性肺纤维化，系统性硬化相关的间质性肺病，尘肺病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Pirfenidone (JAN/USAN/INN)、AMR-69、AP-01

+ [18]

靶点-

作用机制-

治疗领域

呼吸系统疾病其他疾病肿瘤+ [5]

在研适应症

特发性肺纤维化系统性硬化相关的间质性肺病尘肺病+ [9]

非在研适应症

急性心肌梗塞同种异体移植排斥反应外源性变应性肺泡炎+ [15]

原研机构

InterMune, Inc.

在研机构

北京康蒂尼药业股份有限公司

Genentech, Inc.Viatris Ltd. (New Zealand)

+ [9]

非在研机构

Hoffmann-La Roche, Inc.Roche Pharma AG

天津睿瀛生物科技有限公司

+ [4]

最高研发阶段批准上市

首次获批日期

日本 (2008-10-16),

特发性肺纤维化

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

分子式C12H11NO

InChIKeyISWRGOKTTBVCFA-UHFFFAOYSA-N

CAS号53179-13-8

关联

205

项与吡非尼酮相关的临床试验

NCT06241560

/ Not yet recruiting临床2期

An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another.
Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet.
Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.

开始日期2025-01-24

申办/合作机构

Boehringer Ingelheim GmbH

KCT0009628

/ Not yet recruiting临床4期IIT

A Multicenter, Double blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Pirfenidone vs Placebo in Patients with Progressive Pulmonary Fibrosis

开始日期2024-12-31

申办/合作机构

Asan Medical Center

IRCT20240804062647N2

/ RecruitingN/A

Bioequivalence study of Pirfenidone 200 mg tablets produced by Actoverco pharmaceutical company with the reference drug Pirfenex 200 mg manufactured by CIPLA LTD company

开始日期2024-12-21

申办/合作机构-

100 项与吡非尼酮相关的临床结果

登录后查看更多信息

100 项与吡非尼酮相关的转化医学

登录后查看更多信息

100 项与吡非尼酮相关的专利（医药）

登录后查看更多信息

1,958

项与吡非尼酮相关的文献（医药）

2025-03-01·Biomaterials advances

The application and prospects of drug delivery systems in idiopathic pulmonary fibrosis

Review

作者: Tian, Jiahua ; Zhang, Longju ; Zhang, Ling ; Wu, Manli ; Li, Yunfei ; Gong, Ling ; Zhang, Xi ; Qin, Xiaofei

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease primarily affecting elderly individuals aged >65 years and has a poor prognosis. No effective treatment is currently available for IPF. The two antipulmonary fibrosis drugs nintedanib and pirfenidone approved by the FDA in the United States have somewhat decelerated IPF progression. However, the side effects of these drugs can lead to poor patient tolerance and compliance with the medications. Researchers have recently developed various methods for IPF treatment, such as gene silencing and pathway inhibitors, which hold great promise in IPF treatment. Nevertheless, the nonselectivity and nonspecificity of drugs often affect their efficacies. Drug delivery systems (DDS) are crucial for delivering drugs to specific target tissues or cells, thereby minimizing potential side effects, enhancing drug bioavailability, and reducing lung deposition. This review comprehensively summarizes the current state of DDS and various delivery strategies for IPF treatment (e.g., nano-delivery, hydrogel delivery, and biological carrier delivery) to completely expound the delivery mechanisms of different drug delivery carriers. Subsequently, the advantages and disadvantages of different DDS are fully discussed. Finally, the challenges and difficulties associated with the use of different DDS are addressed so as to accelerate their rapid clinical translation.

2025-02-01·CLINICAL RADIOLOGY

Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis

Article

作者: Maher, M M ; Henry, M T ; Shet, S ; O'Regan, P W ; Ryan, D J ; Waldron, M G ; O'Mahony, A T ; Bennett, D M ; Henry, P J

AIM:

Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease. Changes in body composition potentially correlate with outcomes in patients with IPF.

MATERIALS AND METHODS:

Patients with IPF on antifibrotic treatment attending a single institution were identified and retrospectively evaluated (n=84). Three groups were formed based on antifibrotic treatment: pirfenidone group, nintedanib group and pirfenidone-nintedanib switch group. Morphomic analysis of muscle quantity (cross-sectional area in cm²) and quality (density in Hounsfield Units) on thoracic computed tomography (CT) was performed using a web-based morphomic segmentation tool. Bilateral erector spinae and pectoralis muscles were measured at pre-defined vertebral levels.

RESULTS:

All three treatment groups showed a statistically significant decline in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (D_LCO), pectoral muscle cross sectional area (PMA), and erector spinae muscle cross-sectional area (ESMA). Muscle density did not change significantly. Differences existed in analytic morphomics between treatment groups. Patients with a pretreatment body mass index (BMI) below 30 were found to have a significantly greater loss of PMA when treated with nintedanib instead of pirfenidone. FVC and D_LCO did not differ between treatment groups.

CONCLUSION:

There were no direct correlations between pulmonary function and morphomic parameters in our entire group of IPF patients. However, between different treatment groups, the rate of muscle bulk loss differed. This is an important consideration for clinicians when deciding on an antifibrotic agent of choice.

2025-02-01·MICROBIAL PATHOGENESIS

Recent advances in TGF-β signaling pathway in COVID-19 pathogenesis: A review

Review

作者: Sargazi, Saman ; Davodabadi, Fatemeh ; Azizi, Seyed Ghader ; Abdollahi, Zahra ; Majidpour, Mahdi ; Sabeti Akbar-Abad, Mahboobeh ; Shahriari, Hossein

The coronavirus disease 2019 (COVID-19) has resulted in approximately 7.0 million fatalities between 2019 and 2022, underscoring a pressing need for comprehensive research into its underlying mechanisms and therapeutic avenues. A distinctive feature of severe COVID-19 is the dysregulated immune response characterized by excessive activation of immune cells and the consequent cytokine storms. Recent advancements in our understanding of cellular signaling pathways have illuminated the role of Transforming Growth Factor Beta (TGF-β) as a pivotal signaling molecule with significant implications for the pathogenesis of infectious diseases, including COVID-19. Emerging evidence reveals that TGF-β signaling, when activated by viral components or secondary pathways, adversely affects diverse cell types, particularly immune cells, and lung tissue, leading to complications such as pulmonary fibrosis. In our review article, we critically evaluate recent literature on the involvement of TGF-β signaling in the progression of COVID-19. We discuss a range of pharmacological interventions, including nintedanib, pirfenidone, corticosteroids, proton pump inhibitors, and histone deacetylase inhibitors, and their potential to modulate the TGF-β pathway in the context of COVID-19 treatment. Additionally, we explore ongoing clinical trials involving mesenchymal stem cells, low-dose radiation therapy, and artemisinin derivatives to assess their impact on TGF-β levels and subsequent clinical outcomes in COVID-19 patients. This review is particularly relevant at this juncture as the global health community continues to grapple with the ramifications of the COVID-19 pandemic, highlighting the urgent need for targeted therapeutic strategies aimed at TGF-β modulation to mitigate disease severity and improve patient outcomes.

224

项与吡非尼酮相关的新闻（医药）

2025-01-06

·GlobeNewswire-Health Care

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the “Board”) as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre’s majority indirectly owned subsidiary in the People’s Republic of China (“PRC”), to focus on other responsibilities at GNI Group Ltd. Songjiang Ma has been appointed Chairman of the Board of Directors of Gyre Pharmaceuticals. Mr. Zhang has served as a Managing Partner of String Capital Management Co., Limited since 2018. Previously he was the Head of Private Equity Investment and Fund of Funds Business at AEON Life Insurance Company, Ltd. From 2011 to 2015, he served as a Managing Partner of Japan Asia Investment Co., Ltd. Prior to joining Japan Asia Investment Co., Mr. Zhang served as a Managing Director at AEA Investors LP and as a Managing Director of Mitsubishi UFJ Securities Co., Ltd. Mr. Zhang currently serves on the board of directors of GNI and Asian Star Co (TSE: 8946). He received his B.S. in Polymer Science from Fudan University and his M.B.A. in Finance from the University of Chicago Booth School of Business. “As we enter a potentially transformative year for the company, we are excited to welcome Mr. Zhang to our Board, where his deep financial background will prove to be invaluable, and I look forward to leveraging his insights,” said Han Ying, Ph.D., CEO of Gyre Therapeutics. “I would also like to thank Dr. Luo for his leadership and contributions as Chairman of the Board. We wish him all the best in his future endeavors.” About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in MASH is based on the company's experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. About Gyre Pharmaceuticals Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2023 net sales of $112.1 million). In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by early 2025. F351 received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for COPD, PAH and ALF/ACLF. In October 2023, Gyre Therapeutics acquired an indirect majority interest in Gyre Pharmaceuticals (also known as Beijing Continent Pharmaceuticals Co., Ltd.). For Investors:Stephen Jasperstephen@gilmartinir.com

高管变更上市批准临床3期突破性疗法

2024-12-27

·药通社

国内上市原研药，却进不去参比目录？

仿制药的参比遴选有固定的流程： 1、首选原研药品。原研药品选择顺序依次为：国内上市的原研药品→经审核确定的国外原研企业在中国境内生产或经技术转移生产的药品→未进口原研药品； 2、在原研药品不适合作为参比制剂的情况下，可选择在美国、日本或欧盟等管理规范的国家获准上市的国际公认的同种药品、经审核确定的在中国境内生产或经技术转移生产的国际公认的同种药品。 3、其他经国家药品监督管理局评估确定具有安全性、有效性和质量可控性的药品。综上，按理来说：参比制剂遴选应当优先选择国内上市原研药品。在国内上市代表着该品种在国内已走一遍上市申请流程，安全性、有效性已得到证实。但也有例外，如本篇罗列部分国内上市原研产品，曾多次进入参比目录征求意见稿审议，却因各种理由未被批准。为何—— 国内上市原研药，却进不去参比目录？ 1、钆双胺注射液（临床用钆类造影剂；销售额近5亿）原研GE Healthcare AS公司，于2005年国内上市。目前国内已上市7个钆类造影剂，除钆双胺注射液之外，均有参比、且均有过评企业。钆双胺注射液于2021年两次纳入第四十一批、第四十五批参比目录征求意见稿审议，均未通过。未通过理由：本品存在安全性风险，审议未通过。 2、吡诺克辛滴眼液（临床用白内障用药；销售额5千万+）原研千寿制药株式会社，于2001年国内上市。吡诺克辛滴眼液共两个规格，5ml:0.25mg和0.75mg:87mg，前者规格持有人有参天制药和湖北远大天天明，该规格无企业做参比遴选。后者规格持有人仅千寿制药，于2021年两次纳入第四十六批、第四十八批参比目录征求意见稿审议，均未通过。未通过理由：拟申请参比制剂缺乏完整充分的有效性数据，审议未通过。 3、注射用磷酸肌酸钠（心血管系统用药；销售额6亿）原研Alfasigma Romania公司，于2000年国内上市。 2021年两次纳入第四十三批、五十批参比目录征求意见稿审议，均未通过。未通过理由：本品已纳入《第一批国家重点监控合理用药药品目录》，相关安全有效性数据有限，审议未通过。该品种用于心脏手术时加入心脏停搏液中保护心肌，2016年的巅峰销量曾高达64亿。2019年被纳入重点监控之后销量腰斩，直至现在已不足6亿。 4、盐酸奥布卡因滴眼液（眼科领域内表面麻醉剂；销售额8千万+）原研参天制药株式会社，于2002年国内上市。此品共两个规格，其中一个2mg规格顺利入选参比目录且已有企业顺利过评，另一个80mg规格于2021年纳入第四十二批征求意见稿，但未通过审议。未通过理由：该规格含防腐剂，存在安全性问题，审议未通过。 5、吡非尼酮胶囊（抗肺纤维化药物；销售额6.5亿+）此产品是国内北京康蒂尼药业股份有限公司自研品种，于2013年上市。吡非尼酮胶囊共两个规格100mg和200mg，200mg规格无企业做参比遴选。100mg规格于2023年纳入第六十九批参比目录征求意见稿审议，但未通过。未通过理由：基于申请人提交的自证资料，暂不支持其作为参比制剂，审议未通过。 6、注射用丙戊酸钠（抗癫痫药；销售额6.5亿+）原研赛诺菲，于2015年国内上市。 2021年纳入参比目录征求意见稿，最终未通过。未通过理由：国内已有可耐受终端灭菌的注射液获批上市，审议未通过。具体来说，丙戊酸钠的小水针注射液最早2019年8月被列入第二十二批正式参比目录，且已有27家企业过评。由于小水针注射液成功纳入参比，此品冻干粉不予通过。 7、单唾液酸四己糖神经节苷脂钠注射液（神经保护剂；销售额近5亿）原研TrbPharmaInd公司，于2003年国内上市。该品种于2020年纳入第二十九批参比目录征求意见稿审议，未通过。未通过理由：本品生产工艺与注册工艺不一致，存在重大质量安全风险，总局已暂停境内销售使用；适应症过于宽泛、临床证据基础薄弱，需进行符合目前技术要求的确证性临床试验并修订说明书。这个理由属于这几个品种里最明确的。据查询，此产品2015年销量巅峰量达到75亿，2016年被要求修改说明书，2017年被CFDA因生产工艺与注册工艺不一致，存在重大质量安全风险为由，暂停境内销售，并被列入重点监控。自此销售直接跌到底，2023年仅剩不到5亿。 8、布地奈德肠溶胶囊（全球首个IgA肾病对因治疗药物；暂无销售数据）最后这个品种和前几个品的情况有所不同。目前布地奈德肠溶胶囊未进口原研药品顺利入选第八十六批正式参比目录，但国内上市的原研药品却未通过。不通过理由：拟申请参比制剂为附条件批准产品，审议未通过。具体来说，2023年11月21日，原研企业Calliditas公司与国内企业Everest Medicines（云顶新耀）达成合作，布地奈德肠溶胶囊在国内附条件批准，附条件批准要求申请人应在上市后继续完成部分研究。注：本文所写年销售额指的是院内加院外销售额，数据来源摩熵医药投稿/内容沟通：华籍美人（Ww_150525）近期精华文章

医药出海申请上市

2024-12-17

·GlobeNewswire-Health Care

Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that Lyn Baranowski, chief executive officer of Avalyn, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:00 p.m. PT in San Francisco. Ms. Baranowski, CEO; Douglas Carlson, CFO, CBO; Howard Lazarus, M.D., FCCP, CMO; and Melissa Rhodes, Ph.D., COO, will also participate in 1x1 meetings with investors. About Avalyn PharmaAvalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication directly to the site of disease. Avalyn’s lead program, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied in the ongoing MIST Phase 2b Study in progressive pulmonary fibrosis (PPF). AP01 has been assessed in over 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety compared to historical data with existing therapies. Avalyn has initiated a Phase 1b study for its second program, AP02, inhaled nintedanib, that is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). For more information, please visit avalynpharma.com and follow us on LinkedIn. Investor Contact:Alex StrausTHRUST Strategic Communicationsalex@thrustsc.comir@avalynpharma.com Media Contact:Marites CoulterDeerfield Groupmarites.coulter@deerfieldgroup.commedia@avalynpharma.com

临床2期临床1期

100 项与吡非尼酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01583	吡非尼酮	L04AX05	DB04951

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
特发性肺纤维化	日本	Shionogi & Co., Ltd.	2008-10-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性硬化相关的间质性肺病	临床3期	中国	GNI Group Ltd.	2023-05-29
尘肺病	临床3期	-	北京康蒂尼药业股份有限公司	2022-04-15
皮肌炎	临床3期	中国	北京康蒂尼药业股份有限公司	2018-06-01
间质性肺疾病	临床3期	中国	北京康蒂尼药业股份有限公司	2017-10-31
硬化肼胝症	临床3期	中国	北京康蒂尼药业股份有限公司	2017-10-31
急性肺损伤	临床2期	中国	北京康蒂尼药业股份有限公司	2023-03-16
乳腺癌	临床2期	中国	北京康蒂尼药业股份有限公司	2023-03-16
急性心肌梗塞	临床2期	中国	北京康蒂尼药业股份有限公司	2022-08-05
心肌纤维化	临床2期	中国	北京康蒂尼药业股份有限公司	2022-08-05
慢性肾病	临床2期	美国	Genentech, Inc.	2020-10-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASTRO2024	临床2期	辐射损伤	134	Pirfenidone plus standard therapy	選積遞築壓餘範齋築憲(選積鬱衊齋製鏇衊艱製) = 齋網簾蓋糧築範醖獵鹹糧構廠觸廠窪蓋蓋醖鬱 (衊顧淵獵簾鹽顧選獵範 ) 更多	积极	2024-10-01
WCLC2024	临床2期	肺损伤 PD-1 inhibitors	14	Pirfenidone	齋齋鑰積窪廠艱鹽積鹽(鬱網廠鹹憲夢顧鹹醖積) = Pirfenidone-related adverse events (≤ grade 2) occurred in 7 patients, including six gastrointestinal reactions and one photosensitivity reaction 遞憲夢鬱淵淵鏇膚獵鏇 (積鏇艱觸鬱獵膚鑰壓網 )	积极	2024-09-07
				Immune Checkpoint Inhibitors
ATS2024	N/A	疾病进展	-	AP01 100 mg BID	積鹹齋憲餘範構願餘簾(糧遞淵網淵窪夢鹽鹽願) = 積襯淵繭鹹網顧積積願製積糧憲網選蓋願膚廠 (選願夢積膚積壓願獵壓 )	-	2024-05-19
				AP01 50 mg QD	積鹹齋憲餘範構願餘簾(糧遞淵網淵窪夢鹽鹽願) = 壓艱鏇遞衊襯築鬱憲鬱製積糧憲網選蓋願膚廠 (選願夢積膚積壓願獵壓 )
ATLAS AP01 (ATS2024)	临床1期	特发性肺纤维化 WRVS \| e-Lung volume	63	Nebulised Pirfenidone 100mg BD	觸蓋醖醖網餘衊鑰襯簾(廠遞憲襯網夢餘餘獵醖) = 鹽糧醖淵遞願蓋範觸遞願網壓鹹鬱遞鹽鬱繭鹽 (範構糧簾範膚顧壓選襯, -5.5% ~ +3.9) 更多	积极	2024-05-19
				Nebulised Pirfenidone 50mg OD	觸蓋醖醖網餘衊鑰襯簾(廠遞憲襯網夢餘餘獵醖) = 觸繭繭淵齋蓋廠積觸築願網壓鹹鬱遞鹽鬱繭鹽 (範構糧簾範膚顧壓選襯, 1.2% ~ 9.5%) 更多
ESC2024	N/A	血管疾病	-	Pirfenidone diet	醖壓膚積醖襯積廠膚夢(鹽廠構獵膚獵壓壓糧遞) = 繭鏇鹽積製蓋膚鬱繭膚構窪淵齋顧築觸憲膚願 (襯膚淵襯鏇窪餘積膚構, 13.02)	-	2024-04-12
				Pirfenidone (Conventional diet)	醖壓膚積醖襯積廠膚夢(鹽廠構獵膚獵壓壓糧遞) = 繭簾觸壓遞願網糧蓋製構窪淵齋顧築觸憲膚願 (襯膚淵襯鏇窪餘積膚構, 19.81)
NCT02622477 (AERplus, Pubmed \| Pneumologie) 人工标引	N/A	特发性肺纤维化	34	Pirfenidone	鑰網糧壓鹹艱壓憲積選(鑰簾願膚糧簾廠鑰遞鏇) = 憲鏇繭艱糧鏇壓築衊鏇觸齋範遞簾願窪遞觸醖 (衊餘衊餘窪憲鹹鏇襯齋 ) 更多	积极	2024-04-01
NCT03221257 (SLSIII, CTgov)	临床2期	系统性硬皮病 \| 间质性肺疾病	51	Placebo (Plac)+Mycophenolate Mofetil (MMF) (Placebo (Plac) + Mycophenolate (MMF))	夢遞鏇壓襯築鑰壓繭蓋(齋繭醖簾網網鏇窪範築) = 選壓醖製鑰艱廠襯鏇窪遞構網網壓鬱壓構衊醖 (觸壓窪願觸壓廠憲構顧, 築糧製繭壓獵鑰鬱膚觸 ~ 鏇餘衊網鏇憲廠鏇選醖) 更多	-	2023-12-15
				Pirfenidone (PFD)+Mycophenolate Mofetil (MMF) (Pirfenidone (PFD) + Mycophenolate (MMF))	夢遞鏇壓襯築鑰壓繭蓋(齋繭醖簾網網鏇窪範築) = 醖窪獵繭構繭構簾鹽鏇遞構網網壓鬱壓構衊醖 (觸壓窪願觸壓廠憲構顧, 醖獵鏇鏇壓鑰獵齋繭窪 ~ 鏇憲夢夢憲簾鹽製簾蓋) 更多
AP01-005 (NEWS) 人工标引	N/A	特发性肺纤维化 \| 间质性肺疾病	100	pirfenidone	淵製積醖醖鏇鏇夢膚襯(齋廠淵鹹遞衊觸繭鏇觸) = 廠鑰網鹽憲遞築糧衊艱糧齋襯廠構蓋構鹹觸衊 (繭鹹膚觸醖觸製襯網顧 )	积极	2023-11-09
AP01-002 (NEWS) 人工标引	临床1期	特发性肺纤维化	69	pirfenidone	艱衊鑰憲膚衊憲範蓋醖(襯繭鏇鹽遞鹹觸築鏇鏇) = 襯艱鏇壓衊顧鹽廠壓構艱夢糧鏇選艱艱選齋衊 (願艱願淵網構衊鹹糧獵, 185.28) 更多	积极	2023-11-09
				pirfenidone	艱衊鑰憲膚衊憲範蓋醖(襯繭鏇鹽遞鹹觸築鏇鏇) = 憲膚製鬱廠憲選膚鑰鬱艱夢糧鏇選艱艱選齋衊 (願艱願淵網構衊鹹糧獵, 271.17) 更多
SITC2023	N/A	肺炎 \| 非小细胞肺癌	48	Pirfenidone	窪願鑰觸糧製構糧遞艱(範繭獵願繭廠網醖網積) = 鏇獵簾遞築鬱壓獵鏇繭簾壓壓鑰鬱鹹範繭願餘 (淵齋遞選鏇鏇選選網遞 )	积极	2023-11-02